click below
click below
Normal Size Small Size show me how
antivirals
clinical neuro 3
| Question | Answer |
|---|---|
| blocks uncoating of virus | amantadine |
| reason for acyclovir/gancyclovir's highly selective toxicity | they act on viral kinases, so only target infected cells |
| viruses treated w/acyclovir | HSV, EBV, VZV |
| viruses treated w/valacyclovir | recurrent HSV-2 or VZV infections |
| famciclovir is used for | acute herpes zoster and recurrent HSV-2 |
| ganciclovir treats | CMV |
| DOC for temporal lobe encephalitis | acyclovir |
| may cause nephrotoxicity | cidofovir |
| MOA of cidofovir | inhibits DNA polymerase; more effective against viral than host cells |
| doesn't require phosphorylation | foscarnet |
| viruses treated w/foscarnet | HSV, VZV, CMV, EBV, HHV-6, HBV, HIV |
| zanamivir age limit | must be >7 yr |
| oseltamivir age limit | must be >1 yr |
| amantadine age limit | must be >1yr |
| rimantadine age limit | adults only |
| MOA of nueraminidase inhibitors | inhibit cleavage of sialic acid, which prevents the release of newly formed viruses |
| MOA of palivizumab | monoclonal Ab that binds to Fusion (F) protein, preventing infection of host cell |
| virus treated by palivizumab | RSV |
| dosing for palivizumab | monthly |
| mechanism of administration for ribavirin | inhaled |
| pts on ribavirin should avoid contact with | pregnant women or women trying to become pregnant |